Lexicon Pharmaceuticals Inc (OQ:LXRX)

Business Focus: Bio Therapeutic Drugs

Apr 18, 2024 08:00 am ET
Lexicon Pharmaceuticals to Host 2024 Investor Day
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the Lexicon 2024 Investor Day on April 22, 2024. The event will be held in New York City from 9:00 a.m. to 12:00...
Apr 03, 2024 08:00 am ET
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior...
Mar 25, 2024 09:20 am ET
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport proteins (SGLT2 and SGLT1), will be delivered during the American College of Cardiology...
Mar 12, 2024 08:00 am ET
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of clinical data from its inTandem3 Phase 3 trial demonstrated that treatment with sotagliflozin resulted in improved glycemic control in patients with type 1...
Mar 11, 2024 07:15 am ET
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended December 31, 2023 and provided an update on key corporate milestones. “2023 was a pivotal year for Lexicon,” said Lonnel Coats, Lexicon’s...
Mar 11, 2024 07:05 am ET
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced it has entered into a securities purchase agreement (the “purchase agreement”) for a private investment in public equity financing that is expected to result in gross proceeds...
Mar 11, 2024 07:00 am ET
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that, following the receipt of recent feedback from FDA, it is preparing to resubmit its New Drug Application (NDA) for sotagliflozin as an adjunct to insulin therapy for glycemic...
Jan 08, 2024 07:00 am ET
Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update...
Dec 21, 2023 04:15 pm ET
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place January 8 – January 12, 2024. Lonnel Coats, Lexicon’s chief executive officer, will make a company...
Nov 30, 2023 07:30 am ET
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has enrolled the first patient in PROGRESS (A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study with an Open-label Extension...
Nov 22, 2023 07:30 am ET
Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2023: 35th Annual Piper Sandler Healthcare Conference6th Annual Evercore ISI HealthCONx...
Nov 12, 2023 02:10 pm ET
INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of clinical data from the SCORED trial demonstrated that clinical benefit from INPEFA® (sotagliflozin) use in heart failure (HF) and major adverse cardiovascular...
Nov 10, 2023 04:01 pm ET
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Healthcare Conference taking place November 14-16, 2023. Jeff Wade, Lexicon’s president and chief financial officer, and Tom Garner, Lexicon’s...
Nov 08, 2023 07:00 am ET
Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30th, 2023 and provided an update on key corporate milestones. “We achieved important milestones this quarter in commercially...
Nov 03, 2023 09:00 am ET
Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2023 financial results on Wednesday, November 8th, 2023 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT)...
Nov 02, 2023 09:00 am ET
Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that five data presentations related to INPEFA® (sotagliflozin) will be delivered during the American Heart Association Scientific Sessions 2023, November 11-13, 2023, at the Pennsylvania...
Nov 01, 2023 09:00 am ET
INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Express Scripts, the pharmacy benefits management (PBM) business of The Cigna Group's Evernorth, has determined that it will place INPEFA on its Basic and High Performance...
Oct 31, 2023 04:01 pm ET
Lexicon Strengthens Management Team With Two New Executives
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Matthew Cullen is joining the company as vice president of value and access, effective November 1, 2023, and Lisa DeFrancesco will join as head of investor relations and corporate...
Oct 30, 2023 04:01 pm ET
New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to sotagliflozin, as well as data from a Lexicon-supported scientific study of patients hospitalized with heart failure who also had...
Oct 17, 2023 04:01 pm ET
Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today highlighted upcoming presentations of two studies demonstrating positive financial impact of INPEFA® (sotagliflozin) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting,...
Oct 13, 2023 09:31 am ET
Thinking about buying stock in Comtech Telecommunications, Tantech Holdings, MDxHealth, Lexicon Pharmaceuticals, or micromobility.com?
NEW YORK, Oct. 13, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CMTL, TANH, MDXH, LXRX, and MCOM.
Oct 11, 2023 09:00 am ET
Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that findings from two studies on the cost-effectiveness and budget impact of INPEFA® (sotagliflozin) will be presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National...
Oct 10, 2023 09:31 am ET
Thinking about buying stock in Immunic, BioXcel Therapeutics, Coherent Corp, Emx Royalty, or Lexicon Pharmaceuticals?
NEW YORK, Oct. 10, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMUX, BTAI, COHR, EMX, and LXRX.
Oct 09, 2023 04:01 pm ET
INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Express Scripts, the pharmacy benefits management (PBM) business of The Cigna Group's Evernorth, has determined that it will place INPEFA on its Premier Access and Premier...
Oct 09, 2023 08:00 am ET
Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Tom Garner is joining the company as senior vice president and chief commercial officer, effective October 9, 2023. Mr. Garner has over 25 years of pharmaceutical industry...
Sep 28, 2023 09:00 am ET
Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a new analysis of clinical trial data for INPEFA® (sotagliflozin) will be presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, October 6-9, 2023 in...
Sep 26, 2023 09:00 am ET
Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced several upcoming Lexicon-supported data presentations related to heart failure (HF), type 1 diabetes (T1D), and diabetic peripheral neuropathic pain (DPNP). The oral presentations will be...
Sep 07, 2023 04:30 pm ET
Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the H.C. Wainwright & Co. 25th Annual Global Investment Conference, taking place September 11-13, 2023. Jeffrey L. Wade, Lexicon’s president and chief financial...
Sep 07, 2023 09:00 am ET
Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of five upcoming scientific presentations on its investigational drug LX9211, which is being evaluated in clinical trials for the treatment of diabetic peripheral neuropathic...
Aug 21, 2023 09:00 am ET
Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™ (sotagliflozin), its recently approved drug for heart failure, as well as Lexicon-supported data relating to changing patterns...
Aug 08, 2023 09:00 am ET
Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of data from the SOLOIST-WHF Phase 3 outcomes study of sotagliflozin has been published by the Journal of the American College of Cardiology (JACC): Heart...
Aug 03, 2023 04:01 pm ET
Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2023 and provided an update on key corporate milestones. “This was a an important and productive quarter for...
Jul 28, 2023 04:01 pm ET
Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2023 financial results on Thursday, August 3rd, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT)...
Jul 28, 2023 08:00 am ET
Lexicon Elects Diane E. Sullivan to Board of Directors
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Diane E. Sullivan has been elected to its Board of Directors. Ms. Sullivan brings extensive commercialization, strategy, and market access experience to the Lexicon Board of...
Jun 23, 2023 08:45 pm ET
Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced plans to advance its investigational drug LX9211 into late-stage development in a clinical program directed towards an application for regulatory approval in diabetic peripheral...
Jun 20, 2023 08:00 am ET
Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific Sessions
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that clinical study results relating to LX9211, its investigational drug for the treatment of diabetic peripheral neuropathic pain, and INPEFA™ (sotagliflozin), its recently approved drug...
Jun 15, 2023 05:00 pm ET
UPDATE: Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has approved INPEFA™ (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart...
Jun 06, 2023 04:01 pm ET
Lexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies 2023 Global Healthcare Conference, taking place June 7-9, 2023. Lonnel Coats, Lexicon’s chief executive officer, Jeffrey L. Wade, Lexicon’s president...
Jun 05, 2023 04:01 pm ET
Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the closing of Lexicon’s previously announced public offering and concurrent private placement of shares of its common stock. The closing included the issuance and sale of an additional...
Jun 01, 2023 08:00 am ET
Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 23,924,705 shares of its common stock, par value $0.001. The shares of common stock being offered...
May 31, 2023 04:01 pm ET
Lexicon Announces Proposed Public Offering of Common Stock
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition,...
May 26, 2023 04:05 pm ET
Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has approved INPEFA™ (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart...
May 10, 2023 04:30 pm ET
New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart Failure
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that results of a new investigator-initiated economic analysis, based on results from the SOLOIST-WHF Phase 3 outcomes study of its investigational medicine sotagliflozin, were presented...
May 02, 2023 04:00 pm ET
Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2023 and provided an update on key corporate milestones. “Our NDA for sotagliflozin for the treatment of heart failure is on track...
Apr 28, 2023 04:00 pm ET
Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2023 financial results on Tuesday, May 2, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day...
Apr 21, 2023 09:00 am ET
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that results from RELIEF-PHN-1, a Phase 2 double-blind, placebo-controlled trial of its investigational drug LX9211 for the treatment of postherpetic neuralgia, will be presented during...
Apr 17, 2023 04:00 pm ET
Lexicon Pharmaceuticals to Participate in The 22nd Annual Needham Virtual Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, taking place April 17-20, 2023. Lonnel Coats, Lexicon’s chief executive officer, Jeffrey L. Wade, Lexicon’s...
Mar 04, 2023 12:00 pm ET
New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational product sotagliflozin presented at the American College of Cardiology’s 72nd Annual Scientific...
Mar 04, 2023 10:00 am ET
Lexicon Reveals “INTO THE DARK” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the launch of a new disease awareness campaign focused on the cyclical nature of rehospitalizations for heart failure (HF) patients. The “INTO THE DARK” campaign focuses on the first 30...
Mar 02, 2023 04:00 pm ET
Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended December 31, 2022 and provided an update on key corporate milestones. “We are on track for the PDUFA action date in May of this...
Feb 28, 2023 05:00 pm ET
Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2022 financial results on Thursday, March 2, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that...
Feb 20, 2023 08:00 am ET
New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational sotagliflozin product at the American College of Cardiology’s 72nd...
Jan 06, 2023 04:05 pm ET
Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 41st Annual JP Morgan Healthcare Conference, taking place January 9-12, 2023. Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation...
Dec 21, 2022 04:29 pm ET
Lexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced topline results of RELIEF-PHN-1, its Phase 2 proof-of-concept study of LX9211 in postherpetic neuralgia. LX9211 achieved a reduction in average daily pain score (ADPS) of 2.42 from...
Nov 28, 2022 08:00 am ET
Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2022: 34th Annual Piper Sandler Healthcare Conference5th Annual Evercore ISI HealthCONx...
Nov 14, 2022 04:03 pm ET
Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therape
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that full results from the RELIEF-DPN-1 trial of its investigational drug LX9211 were presented at the 16th Annual Pain Therapeutics Summit in Washington, D.C. The oral presentation,...
Nov 11, 2022 08:58 am ET
Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 13th Annual Jefferies London Healthcare Conference, taking place November 15-17, 2022. Jeff Wade, Lexicon’s president and chief financial officer, will make a...
Nov 09, 2022 04:01 pm ET
Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2022 and provided an update on key corporate milestones. “Our mid-cycle review meeting with the FDA was held this week for our...
Nov 08, 2022 08:58 am ET
Lexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics Summit
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the final results from the Phase 2 RELIEF-DPN-1 trial of its investigational drug LX9211, a novel, highly selective inhibitor of adaptor-associated kinase 1 (AAK1), will be presented...
Nov 06, 2022 05:29 pm ET
New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational heart failure treatment sotagliflozin, was presented at the American Heart Association...
Nov 05, 2022 10:35 am ET
New Analysis of SCORED Trial Demonstrates Sotagliflozin’s Effect on Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a new post hoc analysis of results from the SCORED Phase 3 outcomes trial of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, was presented at the American Society...
Nov 04, 2022 08:58 am ET
Lexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2022 financial results on Wednesday, November 9, 2022, after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET / 4:00 p.m. CT...
Oct 31, 2022 08:59 am ET
New Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular Risk Patients to be Presented at the American Heart Association Scientific Sessions 2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF and SCORED Phase 3 outcomes studies of its investigational sotagliflozin product at the American Heart...
Oct 24, 2022 08:59 am ET
Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the following two oral presentations relating to its investigational drug LX9211 will be delivered virtually during the World Brain Disorders and Neuroscience Summit 2022 Hybrid in...
Oct 02, 2022 01:00 pm ET
New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Recurrent Heart Failure Events
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a new analysis of results from the SOLOIST-WHF Phase 3 outcomes trial of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, was presented at the Heart Failure Society...
Sep 20, 2022 08:59 am ET
Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of scientific and medical presentations describing the progression of its investigational drug LX9211 from discovery to translation in a clinical proof-of-concept study. A...
Aug 22, 2022 04:05 pm ET
Lexicon Pharmaceuticals Highlights Publications Relating to Sotagliflozin's Differentiated Dual SGLT1 and SGLT2 Mechanism of Action and Potential Implications for Cardiovascular Disease
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of publications concluding that sotagliflozin’s differentiated dual SGLT1 and SGLT2 mechanism of action may have implications for cardiovascular disease. Two posters will be...
Aug 05, 2022 04:59 pm ET
Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the issuance and sale of an additional 2,526,540 shares of its common stock, par value $0.001 (the “Common Stock”), pursuant to the full exercise of the underwriters’ option...
Aug 02, 2022 04:01 pm ET
Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2022 and provided an update on key milestones. “We received acceptance last week of our New Drug Application (NDA) for sotagliflozin...
Jul 29, 2022 08:00 am ET
Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2022 financial results on Tuesday, August 2, 2022 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET / 4:00 p.m. CT that...
Jul 28, 2022 07:00 am ET
Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 16,843,600 shares of its common stock, par value $0.001 (the “Common Stock”). The shares of Common...
Jul 27, 2022 04:01 pm ET
Lexicon Announces Proposed Public Offering Of Common Stock
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001 (the “Common...
Jul 27, 2022 07:59 am ET
Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and filed its New Drug Application (NDA) for sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, for...
Jun 29, 2022 04:01 pm ET
Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced top-line results of RELIEF-DPN-1, its Phase 2 proof-of-concept study of LX9211 in painful diabetic neuropathy. LX9211 achieved the primary endpoint of the study, demonstrating a...
Jun 01, 2022 08:00 am ET
Lexicon Pharmaceuticals to Participate in the Jefferies 2022 Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022 at 10:00 a.m. ET. A webcast of the event will be...
May 31, 2022 08:00 am ET
Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of sotagliflozin for the treatment of heart...
May 05, 2022 06:00 am ET
Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2022 and provided an update on key milestones. “We plan to resubmit our New Drug Application (NDA) for sotagliflozin for the...
Apr 29, 2022 08:00 am ET
Lexicon Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 5, 2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2022 financial results on Thursday, May 5, 2022 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET / 7:00 a.m. CT that day...
Apr 07, 2022 08:00 am ET
Lexicon Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, Lexicon’s president and chief financial officer, will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 8:45 a.m. ET. A...
Apr 04, 2022 08:00 am ET
Lexicon Welcomes New Guidelines for the Management of Heart Failure
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) welcomes new guidelines for the management of heart failure issued jointly this past weekend by the American Heart Association (AHA), the American College of Cardiology (ACC) and the Heart Failure...
Apr 02, 2022 12:15 pm ET
Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced results of a new analysis of data from the SCORED Phase 3 clinical trial of sotagliflozin that was presented at the American College of Cardiology’s 71st Annual Scientific Session...
Mar 26, 2022 12:43 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lexicon Pharmaceuticals, Inc. - LXRX
NEW YORK, March 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company") (NASDAQ: LXRX).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Mar 21, 2022 08:01 am ET
New Analysis of Cardiovascular Endpoints in the SCORED Trial to Be Presented at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22)
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that an analysis of sotagliflozin data from the SCORED Phase 3 clinical trial will be presented as a late-breaker at the American College of Cardiology’s 71st Annual Scientific Session...
Mar 17, 2022 04:14 pm ET
Lexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of Sotagliflozin
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it entered into a loan facility with Oxford Finance LLC that provides up to $150 million in borrowing capacity designed primarily to support commercial preparations and the potential...
Mar 12, 2022 06:39 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lexicon Pharmaceuticals, Inc. - LXRX
Pomerantz LLP is investigating claims on behalf of investors of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ: LXRX).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Mar 09, 2022 11:00 am ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Lexicon Pharmaceuticals, Inc. (LXRX) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ:
Mar 08, 2022 07:00 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Lexicon Pharmaceuticals, Inc. (LXRX) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ: LXRX) investors concerning the Company’s possible violations of federal securities laws.
Mar 08, 2022 04:44 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Lexicon Pharmaceuticals, Inc. (LXRX) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ:
Mar 04, 2022 11:49 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lexicon Pharmaceuticals, Inc. - LXRX
Pomerantz LLP is investigating claims on behalf of investors of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ: LXRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Mar 02, 2022 09:37 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lexicon Pharmaceuticals, Inc. - LXRX
NEW YORK, March 2, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company") (NASDAQ: LXRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Feb 28, 2022 06:01 am ET
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Clinical Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today reported financial results for the three months and full-year ended December 31, 2021 and provided an update on key milestones. “We remain focused on advancing sotagliflozin for the millions of...
Feb 28, 2022 06:00 am ET
Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the voluntary withdrawal and planned near-term resubmission of the company’s New Drug Application (NDA) for sotagliflozin to correct a technical issue with the submission recently...
Feb 25, 2022 09:03 pm ET
Lexicon Pharmaceuticals to Host Fourth Quarter 2021 Financial Results Conference Call and Webcast on February 28, 2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2021 financial results on Monday, February 28, 2022 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT)...
Jan 13, 2022 09:00 am ET
Lexicon Pharmaceuticals Outlines Major Potential Value Drivers for 2022 at 40th Annual J.P. Morgan Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is outlining major potential value drivers for 2022 at this morning’s presentation at the 40th Annual J.P. Morgan Healthcare Conference. Lexicon submitted a new drug application (NDA) to the U.S. Food...
Jan 04, 2022 04:05 pm ET
Lexicon Pharmaceuticals to Participate in The 40th Annual J.P. Morgan Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. ET. A webcast of the...
Dec 31, 2021 08:31 am ET
Thinking about buying stock in Assertio Holdings, Siyata Mobile, Insignia Systems, Energy Focus, or Lexicon Pharmaceuticals?
NEW YORK, Dec. 31, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ASRT, SYTA, ISIG, EFOI, and LXRX.
Dec 30, 2021 04:05 pm ET
Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 Diabetes
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of sotagliflozin to reduce the risk of cardiovascular...
Nov 15, 2021 04:30 pm ET
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference and the Piper Sandler 33rd Annual Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its virtual participation in the following conferences: Jefferies London Healthcare Conference, taking place November 16-19, 2021Piper Sandler 33rd Annual Healthcare Conference, taking...
Nov 14, 2021 08:35 am ET
Lexicon’s Sotagliflozin Demonstrates Benefits in Heart Failure and Blood Glucose Control Across the Full Range of Kidney Function in New Analysis of Clinical Data
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis evaluating the clinical benefit of Lexicon’s investigational drug, sotagliflozin, in heart failure and blood glucose control across the full range of kidney function...
Nov 09, 2021 08:00 am ET
New Analysis to be Presented at the American Heart Association Scientific Sessions 2021 Evaluating Cardiovascular Benefits Across Baseline Kidney Function
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis of sotagliflozin results from the SOLOIST and SCORED Phase 3 outcomes studies will be presented at the virtual American Heart Association Scientific Sessions 2021....
Nov 03, 2021 04:02 pm ET
Lexicon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2021 and provided an update on key milestones. “We are on track for submission around year-end of our new drug...
Oct 28, 2021 07:27 pm ET
Lexicon Pharmaceuticals to Host Third Quarter 2021 Financial Results Conference Call and Webcast on November 3, 2021
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2021 financial results on Wednesday, November 3, 2021 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT)...
Sep 15, 2021 08:00 am ET
Lexicon Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s president and chief executive officer, will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 21, 2021...
Aug 30, 2021 09:31 am ET
Thinking about buying stock in Marqeta, Lexicon Pharmaceuticals, Kala Pharmaceuticals, Owlet, or New Oriental Education?
NEW YORK, Aug. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MQ, LXRX, KALA, OWLT, and EDU.
Aug 30, 2021 07:00 am ET
Lexicon Welcomes New ESC Heart Failure Treatment Guidelines Establishing SGLT Inhibitors as Standard of Care
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) welcomes the new recommendation by the European Society of Cardiology (ESC) to add SGLT inhibitors as part of the standard of care for the prevention and treatment of heart failure (HF). SGLT inhibitors...
Aug 23, 2021 06:09 am ET
Lexicon’s Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints: Results from Soloist and Scored Trials
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today presented additional analyses of sotagliflozin data from the SOLOIST and SCORED Phase 3 clinical trials at ESC Congress 2021 - The Digital Experience. Sotagliflozin is a first-in-class,...
Jul 30, 2021 09:31 am ET
Thinking about buying stock in Lexicon Pharmaceuticals, Agile Therapeutics, Summit Wireless, Resonant, or Nokia?
NEW YORK, July 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LXRX, AGRX, WISA, RESN, and NOK.
Jul 30, 2021 07:01 am ET
Craig Granowitz, M.D., Ph.D. Joins Lexicon as Senior Vice President and Chief Medical Officer
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that Craig Granowitz, M.D., Ph.D. will join the company as senior vice president and chief medical officer, effective August 2, 2021. Dr. Granowitz joins Lexicon with deep and...
Jul 30, 2021 07:00 am ET
Lexicon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2021 and provided an update on key milestones. “We remain on track to submit our New Drug Application (NDA) for sotagliflozin in...
Jul 28, 2021 05:40 pm ET
Lexicon Pharmaceuticals to Host Second Quarter 2021 Financial Results Conference Call and Webcast on July 30, 2021
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2021 financial results on Friday, July 30, 2021 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that...
Jun 25, 2021 08:00 am ET
Lexicon Pharmaceuticals Announces Symposium at the American Diabetes Association 81st Scientific Sessions
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today there will be a symposium highlighting sotagliflozin followed by a live video question and answer period during the American Diabetes Association’s 81st Scientific Sessions being held...
May 26, 2021 04:15 pm ET
Lexicon Pharmaceuticals to Participate in the 2021 Jefferies Virtual Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s president and chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:30 a.m. ET. A...
May 13, 2021 04:15 pm ET
Lexicon Pharmaceuticals Announces Two Presentations at the American College of Cardiology’s 70th Annual Scientific Session
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today there will be two virtual presentations highlighting sotagliflozin during the American College of Cardiology’s 70th Annual Scientific Session (ACC.21) being held May 15, 2021 through May...
May 06, 2021 04:05 pm ET
Lexicon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2021 and provided an update on key milestones. “We continue to enroll patients in our two proof-of-concept Phase 2 clinical studies...
Apr 29, 2021 04:13 pm ET
Lexicon Pharmaceuticals to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 6, 2021
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2021 financial results on Thursday, May 6, 2021 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day...
Apr 08, 2021 04:35 pm ET
Lexicon Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, Lexicon’s executive vice president, corporate and administrative affairs and chief financial officer, will participate in a live fireside chat at the 20th Annual...
Mar 10, 2021 04:10 pm ET
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Clinical Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended December 31, 2020 and provided an update on key milestones. “During 2020, we substantially strengthened our balance sheet by...
Mar 04, 2021 04:05 pm ET
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast on March 10, 2021
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2020 financial results on Wednesday, March 10, 2021 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET...
Jan 14, 2021 08:00 am ET
Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies can support a new drug application...
Jan 06, 2021 08:00 am ET
Lexicon Pharmaceuticals to Participate in the 39th Annual J.P. Morgan Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s president and chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 2:50 p.m. ET.  A...
Dec 31, 2020 08:00 am ET
Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing in RELIEF-PHN 1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of post-herpetic neuralgia. LX9211...
Dec 16, 2020 04:05 pm ET
Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has entered a collaboration enabling the use by AC Bioscience LTD of preclinical and clinical data for LX2931 without granting any right or license under any of Lexicon’s patent...
Dec 11, 2020 08:01 am ET
Lexicon Announces Offering of Common Stock
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it had entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale, in a registered direct offering, of 20,312,500 shares of...
Dec 11, 2020 07:37 am ET
Lexicon Pharmaceuticals Receives Fast Track Designation From the FDA for LX9211 for Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of LX9211 in diabetic peripheral neuropathic pain. “The FDA’s Fast...
Dec 11, 2020 07:30 am ET
Thinking about buying stock in Walt Disney, vTv Therapeutics, 22nd Century Group, Lexicon Pharmaceuticals, or Ardelyx?
NEW YORK, Dec. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DIS, VTVT, XXII, LXRX, and ARDX.
Dec 08, 2020 08:31 am ET
Thinking about buying stock in Pfizer, Nio, Lexicon Pharmaceuticals, Oncolytics Biotech, or Boeing?
NEW YORK, Dec. 8, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, NIO, LXRX, ONCY, and BA.
Nov 17, 2020 07:30 am ET
Thinking about buying stock in Tesla, FuelCell Energy, Lexicon Pharmaceuticals, Electrameccanica Vehicles, or Outlook Therapeutics?
NEW YORK, Nov. 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, FCEL, LXRX, SOLO, and OTLK.
Nov 16, 2020 10:01 pm ET
Results From SOLOIST and SCORED Outcomes Studies Presented at Late-Breaking Science Session of American Heart Association Scientific Sessions and Published in The New England Journal of Medicine
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations...
Nov 16, 2020 08:00 am ET
Lexicon Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conference: Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020 Lonnel Coats, Lexicon’s president and chief executive officer,...
Oct 29, 2020 06:00 am ET
Lexicon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2020 and provided an update of key milestones. “In the third quarter, we streamlined our operations to prioritize our focus...
Oct 27, 2020 08:00 am ET
Lexicon Pharmaceuticals to Host Third Quarter 2020 Financial Results Conference Call and Webcast on October 29, 2020
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2020 financial results on Thursday, October 29, 2020 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT)...
Sep 23, 2020 06:43 pm ET
Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into separate, privately-negotiated exchange agreements with certain holders of its 5.25% Convertible Senior Notes due 2021 under which such holders have agreed to...
Sep 08, 2020 04:05 pm ET
Lexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera Therapeutics
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today the completion of the sale of Lexicon’s rights, title and interest in XERMELO® (telotristat ethyl) to TerSera Therapeutics LLC.  Lexicon received $160.4 million in cash at closing,...
Sep 04, 2020 08:00 am ET
Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing with blinded study drug in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of diabetic...
Sep 03, 2020 06:00 pm ET
Lexicon Pharmaceuticals to Participate in the Citi 15ᵗʰ Annual BioPharma Virtual Conference and the Wells Fargo 2020 Virtual Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conferences: Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020Wells Fargo 2020 Virtual Healthcare Conference on Thursday,...
Aug 03, 2020 07:25 am ET
GTCR and TerSera Therapeutics Announce Acquisition of Xermelo
CHICAGO, Aug. 3, 2020 /PRNewswire/ -- GTCR, a leading private equity firm, announced today that its TerSera Therapeutics LLC ("TerSera") portfolio company has entered into a definitive agreement to acquire the product Xermelo® (telotristat ethyl) from Lexicon Pharmaceuticals, Inc. ("Lexicon"; NASDAQ:LXRX) for an upfront purchase price of approximately $159 million plus potential milestone payments based on development and commercialization of Xermelo in a new indication.
Jul 30, 2020 10:35 am ET
Thinking about buying stock in Edesa Biotech, iBio Inc, Pfizer Inc, Lexicon Pharmaceuticals, or Apache Corp?
NEW YORK, July 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EDSA, IBIO, PFE, LXRX, and APA.
Jul 30, 2020 07:15 am ET
Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it is realigning its business around its research and development assets, with a focus on its LX9211 neuropathic pain program, now in Phase 2 clinical development.  In that regard:...
Jul 30, 2020 07:10 am ET
Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and TerSera Therapeutics LLC announced today that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicon’s rights, title and interest in XERMELO® (telotristat...
Jul 30, 2020 07:00 am ET
Lexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended June 30, 2020. “We achieved 21% growth in XERMELO net sales in the U.S. for the second quarter of 2020...
Jul 23, 2020 07:00 am ET
Lexicon Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call and Webcast on July 30, 2020
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2020 financial results on Thursday, July 30, 2020 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day...
Jul 21, 2020 09:31 am ET
Thinking about buying stock in New Age Beverages, Lexicon Pharmaceuticals, Miragen Therapeutics, Opko Health, or Niu Technologies?
NEW YORK, July 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NBEV, LXRX, MGEN, OPK, and NIU.
Jul 21, 2020 07:00 am ET
Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies in Type 2 Diabetes
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline data from four Phase 3 sotagliflozin studies in type 2 diabetes: SOTA-MONO, SOTA-SU, SOTA-GLIM and SOTA-INS. The final results of these studies will be preserved for upcoming...
Jul 20, 2020 07:00 am ET
Lexicon Pharmaceuticals Announces Poster Presentations at the Virtual Cholangiocarcinoma Foundation Annual Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that four posters highlighting XERMELO® (telotristat ethyl) will be presented at the virtual Cholangiocarcinoma Foundation Annual Conference (July 22-24). Posters Kim, R. et al....
Jun 13, 2020 11:01 am ET
Lexicon Pharmaceuticals Presents Clinical Data at 80th American Diabetes Association Scientific Sessions
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today presented six posters for ZynquistaTM (sotagliflozin) at the virtual 80th American Diabetes Association (ADA) Scientific Sessions including additional efficacy and safety data patients with type...
May 27, 2020 07:00 am ET
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)  today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference: Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 2:00 p.m. ET The...
May 13, 2020 05:30 pm ET
Lexicon Pharmaceuticals Announces Preclinical Efficacy Data on Telotristat Ethyl’s Antiproliferative Effects Against Various Cancer Cell Lines
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell lines that were published online in...
Apr 27, 2020 07:00 am ET
LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended March 31, 2020. “We achieved 17% growth in XERMELO net sales for the first quarter of 2020 compared to the...
Apr 22, 2020 05:41 pm ET
Lexicon Pharmaceuticals to Host First Quarter 2020 Financial Results Conference Call and Webcast On April 27, 2020
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2020 financial results on Monday, April 27, 2020 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to...
Apr 07, 2020 07:00 am ET
LEXICON PHARMACEUTICALS TO HOST VIRTUAL ANNUAL MEETING OF STOCKHOLDERS ON APRIL 23, 2020
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will host its 2020 annual meeting of stockholders in a virtual format only due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being of meeting participants....
Mar 19, 2020 04:01 pm ET
LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today provided an update on its ZynquistaTM (sotagliflozin) program in type 2 diabetes, heart failure and chronic kidney disease. The company will close out early the two long-term outcomes studies of...
Mar 13, 2020 08:05 am ET
LEXICON PHARMACEUTICALS ANNOUNCES ADDITIONAL DATA ON TELOTRISTAT ETHYL’S ANTIPROLIFERATIVE EFFECTS IN PATIENTS WITH CARCINOID SYNDROME
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the European Neuroendocrine Tumor Society (ENETS)...
Mar 12, 2020 07:00 am ET
LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended December 31, 2019 and provided a business update. “In 2019, we achieved continued growth in our XERMELO (telotristat ethyl)...
Mar 05, 2020 07:00 am ET
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2019 Financial Results Conference Call and Webcast on March 12, 2020
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2019 financial results on Thursday, March 12, 2020 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EST (7:00...
Jan 24, 2020 03:00 pm ET
Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl’s Antiproliferative Effects in Patients With Carcinoid Syndrome
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today real-world data on XERMELO’s® (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the American Society for Clinical Oncology (ASCO)...
Jan 20, 2020 04:01 pm ET
Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from a poster highlighting XERMELO® (telotristat ethyl) will be presented at the American Society for Clinical Oncology (ASCO) 2020 Symposium (January 23-25, San Francisco,...
Jan 06, 2020 06:09 pm ET
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference: 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 7:30...
Dec 20, 2019 07:00 am ET
Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline data from the Phase 3 SOTA-EMPA study for sotagliflozin (Zynquista™) in type 2 diabetes. The topline results are as follows: Sotagliflozin 400 mg achieved the primary endpoint...
Dec 05, 2019 07:00 am ET
Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced positive topline data from the Phase 1 multiple ascending dose study of LX9211, a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1), in development for the...
Dec 03, 2019 07:00 am ET
Lexicon Pharmaceuticals Completes Safety Review of Initial Safety Run-in Cohort of TELE-ABC Study, a Phase 2 Clinical Study of Telotristat Ethyl in Biliary Tract Cancer
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the completion of a safety review of the initial run-in cohort of the Telotristat Ethyl for Advanced Biliary Tract Cancer, or TELE-ABC, study, which is a Phase 2 clinical study of...
Dec 02, 2019 07:00 am ET
Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA’s Office of New Drugs for Sotagliflozin in Type 1 Diabetes
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that the Office of New Drugs of the U.S. Food and Drug Administration (FDA) has reiterated the FDA's prior position and denied Lexicon's appeal of the Complete Response Letter in...
Nov 26, 2019 04:01 pm ET
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer, will present at the following conference: Evercore ISI 2nd Annual...
Nov 14, 2019 08:09 pm ET
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference: Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:35 p.m. EST in...
Nov 07, 2019 07:00 am ET
Lexicon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides a Business Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended September 30, 2019. “We continue to make good progress on our XERMELO business, with XERMELO net sales growing...
Oct 31, 2019 04:01 pm ET
Lexicon Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on November 7, 2019
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2019 financial results on Thursday, November 7, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EST (7:00 a.m. CST) that...
Oct 02, 2019 04:01 pm ET
Lexicon Pharmaceuticals Announces Poster Presentations at the NANETS Annual Multidisciplinary NET Medical Symposium
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from five posters highlighting XERMELO® (telotristat ethyl) will be presented at the upcoming North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical...
Sep 10, 2019 04:01 pm ET
Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the termination of its alliance with Sanofi for the development and commercialization of ZynquistaTM (sotagliflozin) and the settlement of its related disputes with Sanofi, each...
Sep 10, 2019 04:01 pm ET
Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that clinical data for ZynquistaTM (sotagliflozin) will be presented at the upcoming European Association for the Study of Diabetes (EASD) 55th annual meeting (September 16-20;...
Aug 30, 2019 07:00 am ET
Lexicon Pharmaceuticals To Present At Upcoming Investor Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer, will present at the following conference: 2019 Wells Fargo...
Aug 09, 2019 07:00 am ET
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer, will present at the following conference: 2019 Wedbush PacGrow...
Aug 08, 2019 05:23 pm ET
Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista™ (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced positive 52-week cardiorenal results from a pooled analysis from the inTandem1 and inTandem2 studies of Zynquista™ (sotagliflozin) in adults with type 1 diabetes. Zynquista demonstrated...
Jul 31, 2019 07:00 am ET
Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended June 30, 2019. “We are pleased that recent preliminary results of three Phase 3 clinical trials support the...
Jul 30, 2019 12:59 pm ET
Lexicon Pharmaceuticals Announces Date Change for Second Quarter 2019 Financial Results Conference Call and Webcast to July 31, 2019
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has changed the date of its previously announced earnings release, conference call and webcast and will now release financial results for the second quarter of 2019 on Wednesday,...
Jul 26, 2019 05:15 pm ET
Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista™ (Sotagliflozin) Type 2 Diabetes Phase 3 Program
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), received preliminary topline results from Sanofi for three Phase 3 trials of Zynquista™ (sotagliflozin) in adults living with type 2 diabetes from the InSynchrony clinical program. Lexicon has not yet...
Jul 25, 2019 07:00 am ET
Lexicon Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call and Webcast on August 1, 2019
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2019 financial results on Thursday, August 1, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7:00 a.m. CDT) that...
Jun 04, 2019 07:00 am ET
Lexicon Pharmaceuticals to Present New Clinical Data at 79th American Diabetes Association Scientific Sessions
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced new analyses of clinical data for sotagliflozin will be presented at the upcoming 79th American Diabetes Association (ADA) Scientific Sessions in San Francisco, California. The five...
May 23, 2019 07:00 am ET
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer, will present at the following conference: Jefferies 2019...
May 08, 2019 07:00 am ET
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference: Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15, 2019...
May 01, 2019 07:00 am ET
Lexicon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides a Business Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended March 31, 2019. “XERMELO net sales grew more than 20% in the first quarter of 2019 versus the same period in...
Apr 26, 2019 04:01 pm ET
Zynquista™ now Approved in the European Union for Treatment of Adults With Type 1 Diabetes
The European Commission has granted marketing authorization for Zynquista™ (sotagliflozin)*, developed by Sanofi and Lexicon (Nasdaq: LXRX). Zynquista is now approved in the European Union, at once-daily doses of 200 mg and 400 mg, for use as an...
Apr 25, 2019 07:00 am ET
Lexicon Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 1, 2019
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2019 financial results on Wednesday, May 1, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7:00 a.m. CDT) that day...
Apr 10, 2019 08:45 am ET
Consolidated Research: 2019 Summary Expectations for Splunk, Lexicon Pharmaceuticals, Cognizant Technology Solutions, QAD, Walker & Dunlop, and ElectraMeccanica Vehicles — Fundamental Analysis, Key Pe
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Splunk Inc. (NASDAQ:SPLK), Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX),...
Apr 02, 2019 07:00 am ET
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference: 2019 Needham Healthcare Conference on Tuesday, April 9, 2019 at 8:40 a.m. EDT in New...
Apr 01, 2019 02:20 pm ET
CLASS ACTION UPDATE for LXRX, BRS, WTW and AMR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Mar 29, 2019 03:00 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LXRX, UXIN, AVEO and AMRN
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 29, 2019 01:18 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company")(NASDAQ:LXRX) of the April 1, 2019 deadline to seek the role of lead plaintiff in a federal securities...
Mar 27, 2019 10:00 am ET
Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tyme Technologies, Inc. (TYME), Vale S.A. (VALE) & Lexicon Pharmaceuticals, Inc. (LXRX)
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Mar 22, 2019 02:16 pm ET
FDA Issues Complete Response Letter for Zynquista™ (sotagliflozin)
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for investigational Zynquista™ (sotagliflozin)*, a dual SGLT1 and SGLT2 inhibitor for the treatment of adults with type 1...
Mar 22, 2019 02:16 pm ET
Lexicon Pharmaceuticals to Host Conference Call and Webcast Today, March 22, 2019 to Provide a Regulatory Update on Sotagliflozin in Type 1 Diabetes
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that management will conduct a conference call and live webcast today, Friday, March 22, 2019, at 2:45 p.m. EDT (1:45 p.m. CDT) to provide a regulatory update on sotagliflozin, an...
Mar 21, 2019 03:00 pm ET
Class Action Reminder GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Mar 20, 2019 02:44 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Lexicon Pharmaceuticals, Inc. to Contact the Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company") (NASDAQ:LXRX) of the April 1, 2019 deadline to seek the role of lead plaintiff in a federal securities...
Mar 19, 2019 04:25 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Lexicon Pharmaceuticals, Inc. to Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company")(NASDAQ:LXRX) of the April 1, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Mar 15, 2019 03:00 pm ET
(LXRX) Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action & Deadline: April 1, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Lexicon Pharmaceuticals, Inc.  ("Lexicon " or the "Company") (NASDAQ: LXRX) and certain of its officers, on behalf of...
Mar 15, 2019 10:39 am ET
Lexicon Pharmaceuticals Announces Dosing of First Patient in TELE-ABC Study, a Phase 2a Clinical Study of Telotristat Ethyl in Biliary Tract Cancer
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today dosing of the first patient in the Telotristat Ethyl for Advanced Biliary Tract Cancer, or TELE-ABC, study, which is a Phase 2a clinical study of telotristat ethyl in patients with...
Mar 14, 2019 08:57 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – LXRX
Pomerantz LLP announces that a class action lawsuit has been filed against Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ: LXRX) and certain of its officers and directors. The class action, filed in United States District Court,...
Mar 13, 2019 07:00 am ET
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides a Business Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended December 31, 2018 and provided a business update. “In 2018, we achieved continued growth in XERMELO net sales and executed well...
Mar 11, 2019 04:00 pm ET
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Financial Results Conference Call and Webcast on March 13, 2019
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2018 financial results on Wednesday, March 13, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7:00...
Mar 11, 2019 07:00 am ET
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference 
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer, will present at the following conference: Cowen 39th Annual Health...
Mar 07, 2019 07:24 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – LXRX
Pomerantz LLP announces that a class action lawsuit has been filed against Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ: LXRX) and certain of its officers and directors.   The class action, filed in United States District...
Mar 07, 2019 06:20 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company")(NASDAQ:LXRX) of the April 1, 2019 deadline to seek the role of lead plaintiff in a federal securities...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.